🧾 What This Document Is

This is a Schedule 14D-9, a formal "solicitation/recommendation statement." Think of it as Terns' official letter to its shareholders.

Its job? To explain the company's board of directors' recommendation on a major event—in this case, an acquisition offer from pharmaceutical giant Merck. The board is formally telling shareholders: "We recommend you accept Merck's offer and tender your shares."

👉 Why it matters: This document isn't just a formality. It’s the company’s chance to justify a massive decision to its owners (the shareholders), show them the financial details, and explain why selling now is in their best interest.

🏢 What The Company Does

In simple terms, Terns Pharmaceuticals (TERN) is a clinical-stage biotech company. They don't sell drugs yet; they're in the business of developing them.

Focus: They specialize in discovering and developing medicines for metabolic diseases, like liver conditions (NASH) and chronic myeloid leukemia (CML).
Star Asset: Their leading drug candidate is TERN-701, being tested for CML. The promising early clinical data from their "CARDINAL" study is a key reason Merck is interested.
Status: They are a development-stage company, meaning they are years away from bringing a product to market on their own. This is why a partnership or acquisition by a larger company like Merck is a common and logical path forward.

💰 The Deal: Merck's Acquisition Offer

Merck is making a two-part, all-cash offer to buy 100% of Terns.

Upfront Payment: $53.00 per share.
Contingent Value Right (CVR): An additional potential payment of $9.00 per share if Terns' drug TERN-701 gets FDA approval for CML before the 7th anniversary of the deal closing.
Total Potential Value: $62.00 per share.
How it works: It’s structured as a "tender offer" followed by a merger. Shareholders are asked to tender their shares now. Once Merck gets enough, the companies will merge, and the remaining shares will be converted into the right to receive the same cash.

👉 Why it matters: The board unanimously believes this deal delivers certain, immediate cash value for shareholders and eliminates the long-term risk and high cost of developing drugs alone.

📊 What Insiders Stand to Gain

This section is critical because it discloses how the people running the company—executives and directors—will personally benefit from the sale. Their interests might differ from regular shareholders.

Here’s a snapshot of the massive payouts for top executives from their existing stock options and awards, on top of the value of the shares they already own:

Name & Role	Shares Owned (Pre-Deal)	Cash from those Shares	Payout from "In-the-Money" Options	Payout from RSUs
Amy Burroughs (CEO)	147,295	$7.8M	$108.1M	$7.95M
Andrew Gengos (CFO)	33,038	$1.75M	$39.1M	$3.64M
Emil Kuriakose (CMO)	23,720	$1.26M	$47.6M	$4.34M
All Directors & Officers (9 people)	204,053	$10.8M	$239.8M	$15.9M

👉 Why it matters: This table shows why insiders often favor a sale. Their compensation is heavily tied to stock options that become extremely valuable at a set acquisition price. The board was aware of these "different interests" but still recommended the deal.

🤝 The Timeline: How the Deal Came Together

The filing reveals a competitive auction process that started in late 2025 after Terns published great clinical data.

The Spark: Positive data for TERN-701 presented in Dec. 2025 caused Terns' stock to jump from ~$8 to ~$40.
First Offer: An unsolicited bid from "Party C" at $58/share came in Dec. 23, 2025.
The Process: Terns' board formed a committee and hired advisors. They improved the first offer and then reached out to other likely buyers, including Merck, Party A, and Party B.
The Bids: Party C improved to $61 + $9 CVR. Merck bid $61. Party A and B dropped out.
The Twist: Party C withdrew on Feb. 16, 2026, after seeing more nuanced data. This left Merck as the sole remaining serious bidder.
Negotiation: Terns and Merck negotiated the price down from $61 to the final $53 + $9 CVR, along with other legal terms.
Final Approval: On March 24, 2026, the board unanimously approved the deal and recommended shareholders tender their shares.

⚖️ Big Picture: Strengths & Risks

👍 Strengths (Reasons to Support the Deal):

Immediate, Certain Cash: Shareholders get $53/share now, not years of waiting and hoping.
Premium Price: The offer represents a significant premium over Terns' recent trading prices.
Risk Transfer: The immense cost, risk, and uncertainty of drug development are passed to Merck.
Limited Alternatives: After a controlled process, Merck was the only viable bidder left.

⚠️ Risks (Reasons Some Might Oppose):

CVR is Uncertain: The additional $9/share is not guaranteed and depends on FDA approval years from now.
Potential for Higher Value: If TERN-701 is hugely successful, shareholders are giving up that long-term upside for a fixed price.
Process Dynamics: The board ceased talks with Merck when it got frustrated with their timeline, potentially leaving money on the table.
Insider Interests: As shown above, executives stand to gain hundreds of millions, which could influence their judgment.

🔮 What's Next

Shareholder Decision: Terns' shareholders must decide whether to tender their shares by the offer's expiration date.
Merger Completion: If successful, the merger will close shortly after, Terns will be delisted, and its stock will cease to exist.
Integration: Terns' operations and its lead drug candidate, TERN-701, will be absorbed into Merck's massive oncology pipeline.

🧠 The Analogy

Imagine you own a small, promising coffee shop that's developing a revolutionary new espresso blend. A giant global coffee chain like Starbucks offers to buy your shop for a very large, guaranteed cash payment now, plus a smaller bonus if your blend wins a major award in the next few years. You have to decide: do you take the life-changing money now and let them take over the risk, or do you keep grinding, hoping your blend becomes a massive hit that could be worth even more—but could also fail?

🧩 Final Takeaway

Terns' board is unanimously urging shareholders to take the guaranteed money from Merck now. They argue the $53 per share upfront cash provides certain value and eliminates the massive risks of developing a drug alone, outweighing the potential future upside tied to the drug's success. The massive payouts to insiders, while significant, were considered by the board in making this recommendation.

Terns Pharmaceuticals, Inc. — SC 14D9 Filing